IGHE and Increased total eosinophil count: Following ERS/ATS guidelines [36], baseline inflammatory biomarkers confirmed a preponderant Type-2 profile with 57 out of 61 patients (93.44%) showing a co-expression of at least 2 different biomarkers, i.e., blood eosinophilia (≥300 cells/μL), total IgE (≥150 UI/mL) and FeNO (≥25 ppb), of the T2 inflammatory trait.